[ad_1]
According to the World Health Organization (WHO), tuberculosis is one of the most dangerous infectious diseases in the world, ranking alongside HIV / AIDS (https://www.who.int/ tb / en /) among the causes of death. One of the goals of the United Nations Sustainable Development Goals for 2030 is to end the tuberculosis epidemic (https://www.un.org/pga/73/event/fight-to- end-tuberculosis /), which requires a global effort to control the multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB) outbreak. MDR-TB is resistant to first-line drugs, isoniazid (INH) and rifampicin (RIF), and XDR-TB has also developed resistance to fluoroquinolone and the injectable compounds used. Early diagnosis and appropriate treatment for both MDR-TB and XDR-TB are therefore essential to prevent further morbidity, mortality and transmission of the disease.
In recent years, an increased spectrum of antimycobacterial resistance has been observed and, as a result, an increased number of cases of MDR and XDR have been observed. Conventional antibiotic susceptibility testing (AST) methods for TB may take a long time to produce results, require extensive laboratory infrastructure and training, and are potentially bio-hazardous. As a result, there is still an under-diagnosis and a gap between acute TB cases and TB reports.
The new PCR base FluoroType MTBDR 2.0 The test identifies the pathogens of TB, as well as several important features of antibiotic resistance in just three hours. The new test detects TB pathogens directly from patient samples, without any culture. In addition, it can be used to detect MDR-TB, that is, resistance to rifampicin and isoniazid, the two most important first-line anti-TB drugs. This new TB screening test is based on the innovative Bruker-Hain Liquid table technology to badyze a multitude of mutations in badociated TB resistance genes.
New FluoroCycler XT is a new high-performance thermal cycler and optical drive that allows Liquid table dosing technology. the FluoroType MTBDR 2.0 The test can detect more than 60 mutations in TB genes, leading to 522 resistance profiles with relevant information to guide treatment. This level of genetic specificity can normally be achieved only with sequencing.
Dr. Jaime Esteban Depto. Microbiology Clínica at the Universidad Autónoma de Madrid said: "We will implement the new high-resolution system FluoroType MTBDR 2.0 test with the new high-performance optical system FluoroCycler XT improve our ability to diagnose acute TB with greater specificity and as quickly as possible. "
the FluoroCycler XT PCR system and the FluoroType MTBDR 2.0 the CE-IVD badysis recorded in January 2019. With their combined launch, the fight against tuberculosis includes a new advanced testing tool to provide superior diagnostic information.
David Hain, Managing Director of Bruker-Hain Diagnostics, said: "With the introduction of the FluoroType MTBDR 2.0 Liquid table In-depth screening test for tuberculosis on our innovative technology FluoroCycler XT platform, Bruker supports the multinational health goal of improving diagnosis to improve personalized treatment of acute tuberculosis. "
About Bruker Corporation (Nasdaq: BRKR)
Bruker enables scientists to make breakthrough discoveries and develop new applications that improve the quality of life. Bruker's high-performance scientific instruments and valuable badytical and diagnostic solutions enable scientists to explore life and materials at the molecular, cellular and microscopic levels. In close collaboration with its customers, Bruker promotes innovation, improving productivity and customer success in molecular life science research, in applied and pharmaceutical applications, in microscopy and in microscopy. nanobadysis, in industrial applications, as well as in cell biology, preclinical imaging, clinical applications. research in physics and proteomics and clinical microbiology. For more information, please visit: www.bruker.com.
About the Bruker-Hain Diagnosis
Bruker-Hain Diagnostics was created after the recent acquisition of a majority stake of Hain Lifescience GmbH as a division for molecular diagnostics (MDx) products in Bruker's Microbiology and Diagnostics business. Hain Lifescience GmbH is the legal manufacturer of the FluoroCycler XT and the MTBDR 2.0 trial. For more information, visit www.hain-lifescience.de.
Investor contact:
Miroslava Minkova
Director of Investor Relations and Corporate Development
Bruker Corporation
T: +1 (978) 663-3660, ext. 1479
E: [email protected]
Contact for media and clients:
David Hain
Bruker-Hain Diagnostics
General manager
Hain Lifescience GmbH
Tel: + 49-171-331-4645
E: [email protected]
SOURCE Bruker Corporation
Related Links
https://www.bruker.com
Source link
